GH vs. MRNA

Last updated Apr 2, 2026

Compare and contrast key facts about Guardant Health, Inc. (GH) and Moderna, Inc. (MRNA).

Performance

GH vs. MRNA - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Guardant Health, Inc. (GH) and Moderna, Inc. (MRNA). The values are adjusted to include any dividend payments, if applicable.

GH vs. MRNA - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018
GH Guardant Health, Inc.	-10.76%	234.34%	12.94%	-0.55%	-72.81%	-22.39%	64.93%	107.87%	-16.49%
MRNA Moderna, Inc.	69.65%	-29.08%	-58.19%	-44.63%	-29.28%	143.11%	434.10%	28.09%	-17.90%

Fundamentals

Market Cap GH : $11.73B MRNA : $19.61B
EPS GH : -$3.30 MRNA : -$7.24
PS Ratio GH : 11.70 MRNA : 10.04
Total Revenue (TTM) GH : $982.02M MRNA : $1.94B
Gross Profit (TTM) GH : $633.01M MRNA : $274.00M
EBITDA (TTM) GH : -$375.72M MRNA : -$2.61B

Returns By Period

In the year-to-date period, GH achieves a -10.76% return, which is significantly lower than MRNA's 69.65% return.

GH

• 1D: -1.32%
• 1M: -1.17%
• YTD: -10.76%
• 6M: 45.49%
• 1Y: 114.62%
• 3Y*: 57.25%
• 5Y*: -10.30%
• 10Y*: —

MRNA

• 1D: -1.52%
• 1M: -5.33%
• YTD: 69.65%
• 6M: 81.27%
• 1Y: 84.20%
• 3Y*: -31.19%
• 5Y*: -17.71%
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

GH vs. MRNA — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

GH

GH Risk / Return Rank: 89
GH Sharpe Ratio Rank: 90
GH Sortino Ratio Rank: 90
GH Omega Ratio Rank: 86
GH Calmar Ratio Rank: 90
GH Martin Ratio Rank: 88

MRNA

MRNA Risk / Return Rank: 77
MRNA Sharpe Ratio Rank: 80
MRNA Sortino Ratio Rank: 78
MRNA Omega Ratio Rank: 73
MRNA Calmar Ratio Rank: 78
MRNA Martin Ratio Rank: 74

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

GH vs. MRNA - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Guardant Health, Inc. (GH) and Moderna, Inc. (MRNA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	GH	MRNA	Difference
Sharpe ratio Return per unit of total volatility	2.01	1.28	+0.74
Sortino ratio Return per unit of downside risk	2.87	2.02	+0.85
Omega ratio Gain probability vs. loss probability	1.35	1.24	+0.11
Calmar ratio Return relative to maximum drawdown	3.97	2.15	+1.81
Martin ratio Return relative to average drawdown	9.81	4.44	+5.36
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

GH vs. MRNA - Sharpe Ratio Comparison

The current GH Sharpe Ratio is 2.01, which is higher than the MRNA Sharpe Ratio of 1.28. The chart below compares the historical Sharpe Ratios of GH and MRNA, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	GH	MRNA	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	2.01	1.28	+0.74
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.15	-0.27	+0.11
Sharpe Ratio (All Time) Calculated using the full available price history	0.22	0.20	+0.02

Correlation

The correlation between GH and MRNA is 0.28, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

GH vs. MRNA - Dividend Comparison

Neither GH nor MRNA has paid dividends to shareholders.

Tickers have no history of dividend payments

Drawdowns

GH vs. MRNA - Drawdown Comparison

The maximum GH drawdown since its inception was -91.03%, roughly equal to the maximum MRNA drawdown of -95.38%. Use the drawdown chart below to compare losses from any high point for GH and MRNA.

Drawdown Indicators

	GH	MRNA	Difference
Max Drawdown Largest peak-to-trough decline	-91.03%	-95.38%	+4.35%
Max Drawdown (1Y) Largest decline over 1 year	-28.73%	-35.51%	+6.78%
Max Drawdown (5Y) Largest decline over 5 years	-90.30%	-95.38%	+5.08%
Current Drawdown Current decline from peak	-49.11%	-89.67%	+40.56%
Average Drawdown Average peak-to-trough decline	-51.83%	-55.87%	+4.04%
Ulcer Index Depth and duration of drawdowns from previous peaks	11.62%	17.21%	-5.59%

Volatility

GH vs. MRNA - Volatility Comparison

The current volatility for Guardant Health, Inc. (GH) is 12.83%, while Moderna, Inc. (MRNA) has a volatility of 22.27%. This indicates that GH experiences smaller price fluctuations and is considered to be less risky than MRNA based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	GH	MRNA	Difference
Volatility (1M) Calculated over the trailing 1-month period	12.83%	22.27%	-9.44%
Volatility (6M) Calculated over the trailing 6-month period	40.46%	50.95%	-10.49%
Volatility (1Y) Calculated over the trailing 1-year period	57.26%	66.40%	-9.14%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	67.04%	66.59%	+0.45%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	68.16%	72.29%	-4.13%

Financials